Albuterol half life
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Half-Life: Pharmacokinetics and Bioavailability
Introduction to Albuterol Pharmacokinetics
Albuterol, a beta-2 adrenergic agonist, is widely used as a bronchodilator for the relief of bronchospasm in conditions such as asthma. Understanding its pharmacokinetics, particularly its half-life, is crucial for optimizing its therapeutic use and minimizing side effects.
Oral Administration and Half-Life
Studies on the pharmacokinetics of albuterol following oral administration reveal that the drug follows a two-compartment open model with first-order absorption kinetics. In a study involving 12 healthy male volunteers, the elimination phase half-life of albuterol was determined to be approximately 6.5 hours . This finding is consistent with other reports that have observed similar half-life values following single-dose administration.
Comparative Bioavailability and Formulation Differences
The bioavailability and pharmacokinetics of albuterol can vary depending on the formulation. A study comparing three different formulations (two 4-mg tablet formulations and a syrup) found that the elimination phase half-life ranged from 4.8 to 5.5 hours . This slight variation in half-life can be attributed to differences in the inactive excipients used in the formulations.
Inhalation and Pulmonary Absorption
When albuterol is administered via inhalation, the pharmacokinetics differ slightly. In a study where subjects inhaled albuterol using a metered-dose inhaler, the mean elimination half-life was found to be 4.4 hours . This shorter half-life compared to oral administration can be due to the rapid absorption and distribution phases associated with pulmonary delivery.
Urinary Excretion and Metabolic Patterns
Further insights into the pharmacokinetics of inhaled albuterol were provided by a study that measured the urinary excretion of the drug. Approximately 72% of the inhaled dose was excreted within 24 hours, with a calculated half-life of 3.8 hours based on the excretion pattern of unchanged albuterol in urine . This study highlights the efficiency of renal excretion in the elimination of albuterol.
Pediatric Considerations
In pediatric populations, the pharmacokinetics of albuterol can also be influenced by the mode of administration. A study comparing albuterol multidose dry powder inhaler (MDPI) and hydrofluoroalkane (HFA) inhalers in children found comparable pharmacokinetic profiles, with a terminal half-life of elimination similar to that observed in adults . This suggests that the half-life of albuterol remains relatively consistent across different age groups and formulations.
Conclusion
The half-life of albuterol varies slightly depending on the route of administration and formulation, generally ranging from 3.8 to 6.5 hours. These variations are important for clinicians to consider when prescribing albuterol to ensure optimal therapeutic outcomes and minimize potential side effects. Understanding these pharmacokinetic properties helps in tailoring treatment plans for both adult and pediatric patients.
Sources and full results
Most relevant research papers on this topic
Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers.
Inhaled (R,S)-albuterol reaches maximum plasma concentrations in 12.6 minutes, with female subjects experiencing faster peak concentrations and higher mean peak concentrations than male subjects.
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
Albuterol MDPI and HFA have comparable pharmacokinetics and pharmacodynamics in children with asthma after a single 180-g dose.
Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.
Salmeterol 42 microg twice daily significantly improves asthma-specific quality of life, control of symptoms, and pulmonary function compared to albuterol, with sustained improvements over a 12-week period.
DOI